Merck discontinued its Phase 3 BELLWAVE trials and broader nemtabrutinib development program after review found the treatment’s benefits may not outweigh its risks.
https://finviz.com/stock?t=MRK&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.